0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

Errors in Table in: Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration

Arch Ophthalmol. 2010;128(12):1623. doi:10.1001/archophthalmol.2010.623.
Text Size: A A A
Published online

Extract

Errors in Table. In the Clinical Sciences article titled “Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration” by Curtis et al, published in the October issue of the Archives (2010;128[10]:1273-1279), there were errors in Table 4 on page 1277. The corrected Table appears below.

Table 4.Unadjusted and Adjusted Outcomes at 1 Year for the Comparison of Ranibizumab Therapy vs Bevacizumab Therapy Adverse Event No. of Adverse Events/No. (%) of Patients in the Treatment Group Hazard Ratio (95% Confidence Interval)RanibizumabBevacizumabUnadjustedAdjustedaJuly to December 2006bAll-cause mortality647/19026 (4.1)833/21815 (4.7)0.87 (0.76-0.99)0.86 (0.75-0.98)Incident myocardial infarction170/19026 (1.1)227/21815 (1.3)0.84 (0.64-1.08)0.83 (0.64-1.08)Bleeding943/19026 (5.8)1017/21815 (5.6)1.04 (0.92-1.16)1.03 (0.92-1.16)Incident stroke289/19026 (1.8)405/21815 (2.2)0.80 (0.65-0.97)0.78 (0.64-0.96)Exclusive ProviderscAll-cause mortality197/4821 (4.7)225/6147 (4.3)1.11 (0.87-1.43)1.10 (0.85-1.41)Incident myocardial infarction47/4821 (1.1)69/6147 (1.3)0.86 (0.53-1.41)0.87 (0.53-1.41)Bleeding225/4821 (5.3)279/6147 (5.2)1.02 (0.81-1.29)1.01 (0.80-1.28)Incident stroke90/4821 (2.1)129/6147 (2.4)0.88 (0.62-1.26)0.87 (0.61-1.24)

aHazard ratios for ranibizumab compared with bevacizumab after adjustment for the variables listed in Table 1.

bBy the end of the study period, almost all newly treated patients received ranibizumab or bevacizumab as first-line therapy. Therefore, in this secondary analysis, the study population was limited to newly treated patients who received ranibizumab or bevacizumab between July and December 2006.

cPatients with higher socioeconomic status may have been more likely to receive ranibizumab vs bevacizumab, so the primary analysis may have been subject to selection bias. Therefore, in this secondary analysis, the study population was limited to patients who received ranibizumab or bevacizumab in a medical practice that performed at least 20 injections and used a single drug in 95% or more of all intravitreous injections during the third or fourth quarter of 2006.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario

brightcove.createExperiences();